Lifecore Biomedical (NASDAQ:LFCR) versus Contineum Therapeutics (NASDAQ:CTNM) Head-To-Head Survey

Contineum Therapeutics (NASDAQ:CTNM) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Earnings and Valuation

This table compares Contineum Therapeutics and Lifecore Biomedical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50.00 million	12.97	-$59.98 million	($1.73)	-9.97
Lifecore Biomedical	$128.87 million	1.39	-$40.50 million	($1.07)	-4.43

Lifecore Biomedical has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Contineum Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

83.4% of Lifecore Biomedical shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Contineum Therapeutics and Lifecore Biomedical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1	1	3	0	2.40
Lifecore Biomedical	1	2	1	0	2.00

Contineum Therapeutics currently has a consensus price target of $20.25, suggesting a potential upside of 17.46%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 37.13%. Given Lifecore Biomedical’s higher probable upside, analysts clearly believe Lifecore Biomedical is more favorable than Contineum Therapeutics.

Profitability

This table compares Contineum Therapeutics and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Summary

Lifecore Biomedical beats Contineum Therapeutics on 10 of the 14 factors compared between the two stocks.

About Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.